McMaster researchers report EVT0185 may prevent and reverse liver fibrosis by targeting metabolism, offering a promising therapy for MASH with clinical trials expected by 2027.
McMaster researchers report EVT0185 may prevent and reverse liver fibrosis by targeting metabolism, offering a promising therapy for MASH with clinical trials expected by 2027.